News & Updates

Early administration of oral VV116 was noninferior to nirmatrelvir-ritonavir in shortening the time to sustained clinical recovery in individuals with mild-to-moderate COVID-19 who were at high risk for progression to severe disease, a phase III trial has shown. VV116 also had fewer safety issues than nirmatrelvir-ritonavir.

Use of adjunctive intravenous (IV) vitamin C for the management of critically ill patients with COVID-19 infection does not achieve the desired outcome of a reduction in the incidence of mortality, vasopressor requirements, Sequential Organ Failure Assessment (SOFA) scores, or ventilator settings, reports a study.

A recent study has found an increasing prevalence of community-acquired (CA) urinary tract infection (UTI) by emerging spectrum-β-lactamase-producing (ESBL) E. coli in children, with most isolates showing resistance to multiple drugs.

Use of educational pamphlets alone and individualized counselling (IC) both lead to improved uptake of influenza vaccination, reports a Singapore study, noting that IC is not superior to pamphlets alone in increasing uptake.

Outpatient oritavancin therapy appears to be more effective than inpatient standard-of-care (SoC) in reducing 30-day hospital readmissions or admissions among individuals with acute uncomplicated cellulitis, a recent study has shown.

Individuals with rifampin-resistant tuberculosis (RR-TB) may have the option to undergo shorter treatment periods, as findings from the phase II/III TB-PRACTECAL* trial show the noninferiority and superiority of a 24-week, all-oral regimen to standard of care (SoC). It also had a better safety profile than SoC.

Neither vulvovaginal candidiasis nor bacterial vaginosis is associated with increased incidence of cervical cytologic abnormalities among women with or without human papillomavirus (HPV) infection, according to a study. Bacterial vaginosis may even have a protective effect against cytologic abnormalities among women with HPV coinfection.

In the treatment of hospitalized patients with COVID-19, survival outcomes appear to be more favourable with the 8-mg/kg tocilizumab regimen than with the fixed-dose tocilizumab regimen or sarilumab, according to a study.